Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

359

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions
Schizophrenia
Interventions
DRUG

LB-102

LB-102 is a dopamine D2/3 and 5HT7 antagonist.

Trial Locations (25)

10314

Richmond Behavioral Associates, Staten Island

20877

CenExel CBH, Gaithersburg

30030

CenExel iResearch, Decatur

30331

CenExel ACMR, Atlanta

33016

Segal Institute for Clinical Research, Miami Lakes

33021

Behavioral Clinical Research, Inc., Hollywood

33024

CenExel RCA, Hollywood

44720

Neuro-Behavioral Clinical Research, North Canton

45417

Midwest Clinical Research Center, Dayton

60640

Uptown Research Institute, Chicago

60641

Pillar Clinical Research, Chicago

72211

Woodland Internation Research Group, Little Rock

72712

Pillar Clinical Research, Bentonville

72758

Woodland Research Northwest, Rogers

75080

Pillar Clinical Research, Richardson

75115

InSite Clinical Research, DeSoto

78754

Community Clinical Research, Austin

90230

ProScience Research Group, Culver City

90703

Synexus, Cerritos

90706

CelExel Clinical Innovations, Bellflower

91945

Synergy Research, Lemon Grove

92506

CenExel CIT Riverside, Riverside

92705

NRC Research Institute, Santa Ana

92845

CelExel CNS, Garden Grove

08009

CenExel HRI, Berlin

Sponsors
All Listed Sponsors
lead

LB Pharmaceuticals Inc.

INDUSTRY